Filtered By:
Specialty: Cardiology
Drug: Plavix

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 545 results found since Jan 2013.

Ticagrelor in patients with Heart failure after acute coronary syndromes – Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
ConclusionsIn patients with ACS, ticagrelor is more efficacious in protecting against new ischemic events and mortality than clopidogrel, irrespective of the presence of HF. There is no difference between ticagrelor or clopidogrel treatment in new-onset HF post-ACS.
Source: American Heart Journal - April 18, 2019 Category: Cardiology Source Type: research

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis
ConclusionsThe patients in the non-PPI group were observed to be associated with less risk of MACE, myocardial infarction recurrence, stent thrombosis, target vessel revascularization (TVR) and stroke. And the two groups had similar all cause death, cardiovascular death, bleedings events.
Source: IJC Heart and Vasculature - April 2, 2019 Category: Cardiology Source Type: research

Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention
AbstractAlthough it has been reported that prasugrel achieves stronger antiplatelet effect and fewer cardiovascular events compared to clopidogrel in Japanese patients, there are limited data comparing the safety between the 2 dose regimens. Data from 1031 consecutive patients with coronary artery disease undergoing PCI at 5 institutions from May 2014 to April 2016, who received aspirin plus either clopidogrel (619 patients) or prasugrel (412 patients), were retrospectively analyzed. The choice of  clopidogrel or prasugrel was left to the operator's discretion. Adverse events were defined as a composite of bleeding, hepat...
Source: Heart and Vessels - April 2, 2019 Category: Cardiology Source Type: research

Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 　- From the TWMU-AF PCI Registry.
CONCLUSIONS: Low-dose prasugrel, as part of triple therapy, did not increase the risk of bleeding compared with clopidogrel. Therefore, it can be an alternative to clopidogrel for patients with AF undergoing PCI. PMID: 30918236 [PubMed - as supplied by publisher]
Source: Circulation Journal - March 26, 2019 Category: Cardiology Authors: Otsuki H, Yamaguchi J, Kawamoto T, Yoshikawa M, Ebihara S, Tanaka K, Nakao M, Jujo K, Arashi H, Ota Y, Saito K, Takagi A, Tanaka H, Fujii S, Honda A, Mori F, Hagiwara N Tags: Circ J Source Type: research

Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design
ConclusionsThe TICO trial is an ongoing trial evaluating the efficacy and safety of ticagrelor monotherapy following 3-month DAPT exclusively in ACS patients treated with uniform BP-SES. It may provide novel insights regarding the need for adjusted use of DAPT for rebalancing risk–benefit in current practice and changing from the conventional concept of aspirin maintenance to a ticagrelor-based regimen in the management of ACS.
Source: American Heart Journal - March 9, 2019 Category: Cardiology Source Type: research

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research

Increase in ticagrelor use over time is associated with lower rates of ischemic stroke following myocardial infarction
To evaluate the impact of a rapid change in preferred treatment from clopidogrel to ticagrelor on the risk of ischemic stroke following acute myocardial infarction (AMI).
Source: BMC Cardiovascular Disorders - March 4, 2019 Category: Cardiology Authors: Robin Henriksson, Anders Ulvenstam, Lars S öderström and Thomas Mooe Tags: Research article Source Type: research

Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
ConclusionsThe present analysis suggests that prasugrel might have a better efficacy profile than ticagrelor in patients with ACS undergoing PCI. However, this advantage was only seen in pooled observational studies and is likely to be affected by selection bias.
Source: American Journal of Cardiovascular Drugs - March 3, 2019 Category: Cardiology Source Type: research

One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data.
CONCLUSIONS: Among patients aged younger than 75 years, ticagrelor was associated with lower incidence of all-cause mortality. Stroke risk was also reduced in patients with a prescription for ticagrelor without an increase in bleeding risk. PMID: 30770037 [PubMed - in process]
Source: Journal of Cardiology - February 17, 2019 Category: Cardiology Authors: Kim C, Shin DH, Hong SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Hong MK, Park J, Lee H, Kim DS, Oh SK, Jang Y Tags: J Cardiol Source Type: research

Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction
ConclusionIn patients with ESRD and AMI, ticagrelor resulted in numerically fewer but statistically nonsignificant rates of in-hospital and 1-year cardiovascular events with no significant increase in bleeding events compared with clopidogrel.
Source: American Journal of Cardiovascular Drugs - February 12, 2019 Category: Cardiology Source Type: research

Antithrombotic treatment in acute coronary syndrome and atrial fibrillation.
Authors: Darius H, Görge G, Spiecker M, Schinzel H Abstract The number of patients with atrial fibrillation (AF) is increasing due to the aging of the population. In addition, the number of patients with AF and indications for oral anticoagulation (OAC) for the prevention of stroke, who need dual antiplatelet treatment (DAPT) with acetylsalicylic acid (ASA) plus a P2Y12 inhibitor because of an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) is also increasing. In the past these patients received a triple therapy (TT) for 3-12 months. This TT has never been studied for efficacy; how...
Source: Herz - January 30, 2019 Category: Cardiology Tags: Herz Source Type: research

Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review
AbstractPurpose of ReviewAs the management of acute coronary syndrome (ACS) continues to evolve, many old practices proved to be of a little benefit and other approaches established the new pillars of modern medicine. Treating ACS patients with dual antiplatelet therapy (DAPT) for a year by combining aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) has resulted in better outcomes and is currently the standard of therapy. However, owing to the persistent activation of the coagulation cascade, patients may continue to experience recurrent ischemia and high mortality rates despite compliance with the dual...
Source: Current Cardiology Reports - January 28, 2019 Category: Cardiology Source Type: research

Temporary oral anticoagulation after MitraClip - a strategy to lower the incidence of post-procedural stroke?
CONCLUSIONS: Temporary oral anticoagulation might be a strategy to reduce the incidence of stroke within the first 30 days after the MitraClip procedure. Bleeding events were not significantly altered due to temporary oral anticoagulation. PMID: 30650019 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - January 18, 2019 Category: Cardiology Tags: Acta Cardiol Source Type: research

Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS
AbstractThe treatment of patients requiring anticoagulation who develop acute coronary syndrome (ACS) and/or require percutaneous coronary intervention (PCI) must balance the reduction in major adverse cardiovascular events, stroke, and major bleeding. The development of direct oral anticoagulants (DOACs) for the treatment of atrial fibrillation has ushered in an era of potential treatment options for these complex patients.Purpose of ReviewTo review the clinical evidence underlying the use of DOACs for the treatment of patients with atrial fibrillation and ACS or PCI.Recent FindingsThree trials studied this particular pat...
Source: Current Cardiology Reports - January 12, 2019 Category: Cardiology Source Type: research

Short- and Long-Term Follow-up of Antithrombotic Management Patterns in Patients Hospitalized with Acute Coronary Syndrome (ACS): Indian Subgroup of EPICOR-Asia Study
ConclusionThis study showed a gap between international recommendations and implementation for managing ACS in Indian patients.. Most of the patients prefer to undergo invasive management instead of noninvasive therapy.. At the end of 2-year follow up more than half of the population were receiving DAPT, with most patients on receiving a combination of aspirin and clopidogrel The mortality along with composite events of death, MI, or ischemic stroke was highest for NSTEMI patients.
Source: Indian Heart Journal - January 3, 2019 Category: Cardiology Source Type: research